EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

Science Translational Medicine

Volumn 6, Issue 244, 2014, Pages

  Rebouissou, Sandra ^a,b   Bernard Pierrot, Isabelle ^a,b   De Reyniès, Aurélien ^c   Lepage, May Linda ^a,b   Krucker, Clémentine ^a,b   Chapeaublanc, Elodie ^a,b   Hérault, Aurélie ^a,b   Kamoun, Aurélie ^a,b   Caillault, Aurélie ^a,b   Letouzé, Eric ^c   Elarouci, Nabila ^c   Neuzillet, Yann ^d,e   Denoux, Yves ^d   Molinié, Vincent ^f   Vordos, Dimitri ^g   Laplanche, Agnès ^h   Maillé, Pascale ^g   Soyeux, Pascale ^i,j   Ofualuka, Karina ^i,j   Reyal, Fabien ^a,b   Biton, Anne ^a,b,k,n   Sibony, Mathilde ^l   Paoletti, Xavier ^b,k   Southgate, Jennifer ^m   Benhamou, Simone ^h,i   Lebret, Thierry ^d,e   Allory, Yves ^g,i,j   Radvanyi, François ^a,b   more..

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c Ligue Nationale Contre le Cancer   (France)

^d FOCH HOSPITAL   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f SAINT JOSEPH HOSPITAL   (France)

^g HENRI MONDOR HOSPITAL   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ INSERM   (France)

^j FACULTÉ DE MÉDECINE   (France)

^k INSERM U900   (France)

^l Université Paris Est Faculté de Médecine ^*  (France)

^m UNIVERSITY OF YORK   (United Kingdom)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; FOXA1 PROTEIN, HUMAN; KERATIN; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; PROTEIN KINASE INHIBITOR; TRANSCRIPTOME;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOCRINE EFFECT; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER INHIBITION; CANCER PROGNOSIS; CLASSIFIER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUSE; MOUSE MODEL; MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL TIME; TRANSCRIPTOMICS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUSCLE; PATHOLOGY; PHENOTYPE; SIGNAL TRANSDUCTION; SURVIVAL; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR INVASION; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; AUTOCRINE COMMUNICATION; BUTYLHYDROXYBUTYLNITROSAMINE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; KERATINS; MALE; MICE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUSCLES; NEOPLASM INVASIVENESS; PHENOTYPE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSCRIPTOME; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84904479838     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3008970     Document Type: Article

References (40)

1. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, D. M. Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010).
2. R. E. Hautmann, R. C. de Petriconi, C. Pfeiffer, B. G. Volkmer, Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: Long-term results in 1100 patients. Eur. Urol. 61, 1039-1047 (2012).
3. C. N. Sternberg, J. Bellmunt, G. Sonpavde, A. O. Siefker-Radtke, W. M. Stadler, D. F. Bajorin, R. Dreicer, D. J.George, M. I. Milowsky, D. Theodorescu, D. J. Vaughn, M. D. Galsky, M. S. Soloway, D. I. Quinn; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012, ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur. Urol. 63, 58-66 (2013).
4. J. Bellmunt, D. P. Petrylak, New therapeutic challenges in advanced bladder cancer. Semin. Oncol. 39, 598-607 (2012).
5. R. S. Pruthi, M. Nielsen, S. Heathcote, E. M. Wallen, W. K. Rathmell, P. Godley, Y. Whang, J. Fielding, H. Schultz, G. Grigson, A. Smith, W. Kim, A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Clinical and pathological results. BJU Int. 106, 349-354 (2010).
6. Y. N. Wong, S. Litwin, D. Vaughn, S. Cohen, E. R. Plimack, J. Lee, W. Song, M. Dabrow, M. Brody, H. Tuttle, G. Hudes, Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J. Clin. Oncol. 30, 3545-3551 (2012).
7. E. Blaveri, J. P. Simko, J. E. Korkola, J. L. Brewer, F. Baehner, K. Mehta, S. Devries, T. Koppie, S. Pejavar, P. Carroll, F. M. Waldman, Bladder cancer outcome and subtype classification by gene expression. Clin. Cancer Res. 11, 4044-4055 (2005).
8. L. Dyrskjøt, K. Zieger, F. X. Real, N. Malats, A. Carrato, C. Hurst, S. Kotwal, M. Knowles, P. U. Malmström, M. de la Torre, K. Wester, Y. Allory, D. Vordos, A. Caillault, F. Radvanyi, A. M. Hein, J. L. Jensen, K. M. Jensen, N. Marcussen, T. F. Orntoft, Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: A multicenter validation study. Clin. Cancer Res. 13, 3545-3551 (2007).
9. W. J. Kim, S. K. Kim, P. Jeong, S. J. Yun, I. C. Cho, I. Y. Kim, S. K. Moon, H. D. Um, Y. H. Choi, A fourgene signature predicts disease progression in muscle invasive bladder cancer. Mol. Med. 17, 478-485 (2011).
10. D. Lindgren, A. Frigyesi, S. Gudjonsson, G. Sjödahl, C. Hallden, G. Chebil, S. Veerla, T. Ryden, W. Månsson, F. Liedberg, M. Höglund, Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 70, 3463-3472 (2010).
11. M. Riester, J. M. Taylor, A. Feifer, T. Koppie, J. E. Rosenberg, R. J. Downey, B. H. Bochner, F. Michor, Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin. Cancer Res. 18, 1323-1333 (2012).
12. G. Sjödahl, M. Lauss, K. Lövgren, G. Chebil, S. Gudjonsson, S. Veerla, O. Patschan, M. Aine, M. Fernö, M. Ringnér, W. Månsson, F. Liedberg, D. Lindgren, M. Höglund, A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377-3386 (2012).
13. N. Stransky, C. Vallot, F. Reyal, I. Bernard-Pierrot, S. G. de Medina, R. Segraves, Y. de Rycke, P. Elvin, A. Cassidy, C. Spraggon, A. Graham, J. Southgate, B. Asselain, Y. Allory, C. C. Abbou, D. G. Albertson, J. P. Thiery, D. K. Chopin, D. Pinkel, F. Radvanyi, Regional copy number-independent deregulation of transcription in cancer. Nat. Genet. 38, 1386-1396 (2006).
14. F. Bertucci, P. Finetti, D. Birnbaum, Basal breast cancer: A complex and deadly molecular subtype. Curr. Mol. Med. 12, 96-110 (2012).
15. S. Ling, X. Chang, L. Schultz, T. K. Lee, A. Chaux, L. Marchionni, G. J. Netto, D. Sidransky, D. M. Berman, An EGFR-ERK-SOX9 signaling cascade links urothelial development and regeneration to cancer. Cancer Res. 71, 3812-3821 (2011).
16. P. Perrotte, T. Matsumoto, K. Inoue, H. Kuniyasu, B. Y. Eve, D. J. Hicklin, R. Radinsky, C. P. Dinney, Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5, 257-265 (1999).
17. W. I. De Boer, A. B. Houtsmuller, V. Izadifar, B.Muscatelli-Groux, T. H. Van der Kwast, D. K. Chopin, Expression and functions of EGF, FGF and TGFb-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells. Int. J. Cancer 71, 284-291 (1997).
18. P. J. Becci, H. J. Thompson, C. J. Grubbs, R. A. Squire, C. C. Brown, M. B. Sporn, R. C. Moon, Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)- nitrosamine. Cancer Res. 38, 4463-4466 (1978).
19. A. el-Marjou, A. Delouvée, J. P. Thiery, F. Radvanyi, Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression. Carcinogenesis 21, 2211-2218 (2000).
20. K. Morimura, S. Yamamoto, T. Murai, S. Mori, T. X. Chen, H. Wanibuchi, S. Fukushima, LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl) nitrosamine. Carcinogenesis 20, 715-718 (1999).
21. C. Dunois-Lardé, O. Levrel, A. Brams, J. P. Thiery, F. Radvanyi, Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine. Mol. Carcinog. 42, 142-149 (2005).
22. Cancer Genome Atlas Research Network, Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014).
23. W. Choi, S. Porten, S. Kim, D. Willis, E. R. Plimack, J. Hoffman-Censits, B. Roth, T. Cheng, M. Tran, I. L. Lee, J. Melquist, J. Bondaruk, T. Majewski, S. Zhang, S. Pretzsch, K. Baggerly, A. Siefker-Radtke, B. Czerniak, C. P. Dinney, D. J. McConkey, Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152-165 (2014).
24. A. Sadanandam, C. A. Lyssiotis, K. Homicsko, E. A. Collisson, W. J. Gibb, S. Wullschleger, L. C. Ostos, W. A. Lannon, C. Grotzinger, M. Del Rio, B. Lhermitte, A. B. Olshen, B. Wiedenmann, L. C. Cantley, J. W. Gray, D. Hanahan, A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19, 619-625 (2013).
25. J. Y. Douillard, K. S. Oliner, S. Siena, J. Tabernero, R. Burkes, M. Barugel, Y. Humblet, G. Bodoky, D. Cunningham, J. Jassem, F. Rivera, I. Kocakova, P. Ruff, M. Blasinska-Morawiec, M. Smakal, J. L. Canon, M. Rother, R. Williams, A. Rong, J. Wiezorek, R. Sidhu, S. D. Patterson, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 1023-1034 (2013).
26. M.R. Freeman, J. J. Yoo, G. Raab, S. Soker, R. M. Adam, F. X. Schneck, A. A. Renshaw, M. Klagsbrun, A. Atala, Heparin-binding EGF-like growth factor is an autocrine growth factor for human urothelial cells and is synthesized by epithelial and smooth muscle cells in the human bladder. J. Clin. Invest. 99, 1028-1036 (1997).
27. C. Varley, G. Hill, S. Pellegrin, N. J. Shaw, P. J. Selby, L. K. Trejdosiewicz, J. Southgate, Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. Exp. Cell Res. 306, 216-229 (2005).
28. K. S. Chan, I. Espinosa, M. Chao, D. Wong, L. Ailles, M. Diehn, H. Gill, J. Presti Jr., H. Y. Chang, M. van de Rijn, L. Shortliffe, I. L. Weissman, Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. U.S.A. 106, 14016-14021 (2009).
29. X. He, L. Marchionni, D. E. Hansel, W. Yu, A. Sood, J. Yang, G. Parmigiani, W. Matsui, D. M. Berman, Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma. Stem Cells 27, 1487-1495 (2009).
30. P. L. Ho, A. Kurtova, K. S. Chan, Normal and neoplastic urothelial stem cells: Getting to the root of the problem. Nat. Rev. Urol. 9, 583-594 (2012).
31. Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
32. C. H. Chung, J. S. Parker, G. Karaca, J. Wu, W. K. Funkhouser, D. Moore, D. Butterfoss, D. Xiang, A. Zanation, X. Yin, W. W. Shockley, M. C. Weissler, L. G. Dressler, C. G. Shores, W. G. Yarbrough, C. M. Perou, Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5, 489-500 (2004).
33. L. A. Carey, H. S. Rugo, P. K. Marcom, E. L. Mayer, F. J. Esteva, C. X. Ma, M. C. Liu, A. M. Storniolo, M. F. Rimawi, A. Forero-Torres, A. C. Wolff, T. J. Hobday, A. Ivanova, W. K. Chiu, M. Ferraro, E. Burrows, P. S. Bernard, K. A. Hoadley, C. M. Perou, E. P. Winer, TBCRC 001: Randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J. Clin. Oncol. 30, 2615 -2623 (2012).
34. C. Billerey, D. Chopin, M. H. Aubriot-Lorton, D. Ricol, S. Gil Diez de Medina, B. Van Rhijn, M. P. Bralet, M. A. Lefrere-Belda, J. B. Lahaye, C. C. Abbou, J. Bonaventure, E. S. Zafrani, T. van der Kwast, J. P. Thiery, F. Radvanyi, Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am. J. Pathol. 158, 1955-1959 (2001).
35. W. J. Kim, E. J. Kim, S. K. Kim, Y. J. Kim, Y. S. Ha, P. Jeong, M. J. Kim, S. J. Yun, K. M. Lee, S. K. Moon, S. C. Lee, E. J. Cha, S. C. Bae, Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol. Cancer 9, 3 (2010).
36. M. Dai, P.Wang, A. D. Boyd, G. Kostov, B. Athey, E. G. Jones, W. E. Bunney, R.M.Myers, T. P. Speed, H. Akil, S. J. Watson, F. Meng, Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33, e175 (2005).
37. S. Boyault, D. S. Rickman, A. de Reyniès, C. Balabaud, S. Rebouissou, E. Jeannot, A. Hérault, J. Saric, J. Belghiti, D. Franco, P. Bioulac-Sage, P. Laurent-Puig, J. Zucman-Rossi, Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42-52 (2007).
38. S. Monti, K. J. Savage, J. L. Kutok, F. Feuerhake, P. Kurtin, M. Mihm, B. Wu, L. Pasqualucci, D. Neuberg, R. C. Aguiar, P. Dal Cin, C. Ladd, G. S. Pinkus, G. Salles, N. L. Harris, R. Dalla-Favera, T. M. Habermann, J. C. Aster, T. R. Golub, M. A. Shipp, Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 105, 1851-1861 (2005).
39. M. S. Pepe, G. Longton, G. L. Anderson, M. Schummer, Selecting differentially expressed genes from microarray experiments. Biometrics 59, 133-142 (2003).
40. Y. Huang, A. de Reyniès, L. de Leval, B. Ghazi, N. Martin-Garcia, M. Travert, J. Bosq, J. Brière, B. Petit, E. Thomas, P. Coppo, T. Marafioti, J. F. Emile, M. H. Delfau-Larue, C. Schmitt, P. Gaulard, Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood 115, 1226-1237 (2010).